2. Search Result
Search Result
Results for "

Asymmetric dimethylarginine

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-113216
    Asymmetric dimethylarginine
    5 Publications Verification

    NG,NG-dimethylarginine

    		 Endogenous Metabolite NO Synthase Cardiovascular Disease Cancer
    Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS), and functions as a marker of endothelial dysfunction in a number of pathological states.
    Asymmetric dimethylarginine
  • HY-113216BS
    Asymmetric-dimethylarginine-d6 dihydrochloride

    NG,NG-dimethylarginine-d6 dihydrochloride

    		 Endogenous Metabolite NO Synthase Others
    Asymmetric-dimethylarginine-d6 (dihydrochloride) is the deuterium labeled Asymmetric-dimethylarginine dihydrochloride .
    Asymmetric-dimethylarginine-d6 dihydrochloride
  • HY-113216B
    Asymmetric dimethylarginine dihydrochloride

    NG,NG-dimethylarginine dihydrochloride

    		 NO Synthase Cardiovascular Disease Cancer
    Asymmetric dimethylarginine dihydrochloride is an endogenous NO synthase inhibitor that reduces NO production, which contributes to endothelial dysfunction and cardiovascular disease .
    Asymmetric dimethylarginine dihydrochloride
  • HY-159728
    PROTAC PRMT3 degrader 1

    		PROTACs Histone Methyltransferase Apoptosis Early 2 Factor (E2F) c-Myc Cancer
    PROTAC PRMT3 degrader 1 is a selective PRMT3 PROTAC degrader with a DC50 of 2.566 μM. PROTAC PRMT3 degrader 1 forms a ternary complex with MDM2 E3 ubiquitin ligase to induce proteasomal and neddylation-dependent degradation of PRMT3. PROTAC PRMT3 degrader 1 activates intrinsic apoptosis, endoplasmic reticulum stress signaling pathways. PROTAC PRMT3 degrader 1 downregulates E2F, MYC, oxidative phosphorylation pathways. PROTAC PRMT3 degrader 1 reduces cellular asymmetric dimethylarginine (ADMA) levels. PROTAC PRMT3 degrader 1 inhibits acute leukemia cell growth. PROTAC PRMT3 degrader 1 acts with glycolysis inhibitor 2-DG to reduce ATP production, induce intrinsic apoptosis, drive synergistic antiproliferative effects. PROTAC PRMT3 degrader 1 can be used for the research of acute leukemia .
    PROTAC PRMT3 degrader 1
  • HY-113216R
    Asymmetric dimethylarginine (Standard)

    NG,NG-dimethylarginine (Standard)

    		 Reference Standards Endogenous Metabolite NO Synthase Cardiovascular Disease Cancer
    Hesperetin (Standard) is the analytical standard of Hesperetin. This product is intended for research and analytical applications. Hesperetin is a natural flavanone, and acts as a potent and broad-spectrum inhibitor against human UGT activity. Hesperetin regulates apoptosis.
    Asymmetric dimethylarginine (Standard)
  • HY-113216AS
    Asymmetric dimethylarginine-d7 hydrochloride

    NG,NG-dimethylarginine-d7 hydrochloride

    		 Endogenous Metabolite Others
    Asymmetric dimethylarginine-d7 (hydrochloride) is the deuterium labeled Asymmetric dimethylarginine hydrochloride .
    Asymmetric dimethylarginine-d7 hydrochloride
  • HY-113216S
    Asymmetric dimethylarginine-d7 hydrochloride hydrate

    NG,NG-dimethylarginine-d7 hydrochloride hydrate

    		 Isotope-Labeled Compounds Endogenous Metabolite NO Synthase Cardiovascular Disease Cancer
    Asymmetric dimethylarginine-d7 (hydrochloride hydrate) is the deuterium labeled Asymmetric dimethylarginine. Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS), and functions as a marker of endothelial dysfunction in a num
    Asymmetric dimethylarginine-d7 hydrochloride hydrate
  • HY-175821
    PRMT1-IN-3

    		Histone Methyltransferase Apoptosis Cancer
    PRMT1-IN-3 is a potent protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 4.11 μM. PRMT1-IN-3 inhibits PRMT6 and PRMT8 with IC50s of 23.3 and 30.1 μM. PRMT1-IN-3 suppresses asymmetric dimethylarginine (ADMA) levels and histone H4R3me2a modification in triple-negative breast cancer (TNBC) cells. PRMT1-IN-3 induces cell cycle arrest, apoptosis, and inhibits migration and colony formation in MDA-MB-231 cells. PRMT1-IN-3 acts as chemotherapeutic sensitizers for Paclitaxel (HY-B0015). PRMT1-IN-3 can be used for the study of TNBC .
    PRMT1-IN-3
  • HY-178274
    SKLB06329

    		Histone Methyltransferase Apoptosis Cancer
    SKLB06329 is a potent selective Type I PRMTs inhibitor. SKLB06329 shows good selectivity for PRMT6 (IC50 = 3.86 nM) over Type II/III PRMTs (PRMT5/7) and shows no significant inhibition against various lysine methyltransferases (PKMTs). SKLB06329 significantly inhibits the proliferation of triple-negative breast cancer (TNBC) cells, induces apoptosis, and suppresses the expression of asymmetric dimethylarginine (ADMA) within cells. SKLB06329 can be used for triple-negative breast cancer research .
    SKLB06329
  • HY-182275
    PROTAC PRMT1 degrader-1

    		PROTACs Histone Methyltransferase Cancer
    PROTAC PRMT1 degrader-1 (compound 4) is a PRMT1 PROTAC degrader, with a DC50 of 0.77 μM (MCF-7 cells). PROTAC PRMT1 degrader-1 recruits the CRBN E3 ubiquitin ligase to induce proteasome-dependent degradation of PRMT1; it also forms a ternary complex with PRMT1 and CRBN, promoting ubiquitination and subsequent proteasomal degradation of PRMT1. PROTAC PRMT1 degrader-1 reduces the level of asymmetric dimethylarginine in cancer cells, as well as the level of asymmetric dimethylation of arginine 3 on histone H4, while inhibiting the growth of various cancer cells. PROTAC PRMT1 degrader-1 can be used in the research of breast cancer and melanoma .
    PROTAC PRMT1 degrader-1

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: